Spirulina supplement tested to stop chemo nerve pain
NCT ID NCT05025826
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether Phycocare, a supplement made from spirulina, can reduce nerve damage caused by the chemotherapy drug oxaliplatin in people with metastatic gastrointestinal cancers. 73 participants took either Phycocare or a placebo daily for 9 months. The goal was to see if Phycocare could cut the rate of moderate-to-severe neuropathy by half at 4 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Phycocare (phycocyanin from spirulina)
What this could lead to
If it works, this could offer a way to prevent or reduce painful nerve damage caused by oxaliplatin chemotherapy, helping patients stay on treatment longer.
What could go wrong
This is a small, early-stage trial with only 73 participants. The supplement may not reduce neuropathy more than placebo, and results may not apply to all cancer types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier de Cholet
Cholet, 49300, France
-
Chd La Roche Sur Yon
La Roche-sur-Yon, France
-
Clermont-Ferrand UH
Clermont-Ferrand, France
-
Foch Suresnes Hosptial
Suresnes, France
-
Hôpital le Confluent
Nantes, 44000, France
-
Mutaliste Clinic Saint Nazaire
Saint-Nazaire, France
-
Nantes Uh
Nantes, France
-
Saint Gregoire Clinique
Rennes, France